MGO One Seven LLC Has $1.22 Million Stock Holdings in Stryker Co. (NYSE:SYK)

MGO One Seven LLC raised its holdings in Stryker Co. (NYSE:SYK - Free Report) by 38.4% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 3,397 shares of the medical technology company's stock after acquiring an additional 942 shares during the period. MGO One Seven LLC's holdings in Stryker were worth $1,223,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors have also modified their holdings of SYK. Kohmann Bosshard Financial Services LLC bought a new stake in shares of Stryker during the fourth quarter worth $25,000. Rakuten Securities Inc. lifted its holdings in shares of Stryker by 618.2% in the fourth quarter. Rakuten Securities Inc. now owns 79 shares of the medical technology company's stock valued at $28,000 after purchasing an additional 68 shares in the last quarter. Centricity Wealth Management LLC bought a new stake in shares of Stryker in the fourth quarter valued at about $30,000. BankPlus Trust Department bought a new position in shares of Stryker during the fourth quarter worth about $33,000. Finally, VSM Wealth Advisory LLC acquired a new stake in Stryker in the 4th quarter valued at approximately $36,000. Institutional investors own 77.09% of the company's stock.

Wall Street Analysts Forecast Growth

SYK has been the subject of several research reports. JMP Securities reaffirmed a "market perform" rating on shares of Stryker in a research note on Tuesday, February 18th. Citigroup reissued a "buy" rating and set a $450.00 price target on shares of Stryker in a research report on Wednesday, February 26th. Truist Financial lifted their target price on Stryker from $409.00 to $413.00 and gave the company a "hold" rating in a research report on Thursday, January 30th. Stifel Nicolaus increased their price target on Stryker from $400.00 to $440.00 and gave the company a "buy" rating in a research report on Wednesday, January 29th. Finally, Argus set a $450.00 price target on Stryker in a research note on Monday, February 3rd. Five research analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the company's stock. According to MarketBeat.com, Stryker currently has an average rating of "Moderate Buy" and a consensus price target of $423.53.

Stryker Price Performance

SYK traded down $1.25 on Wednesday, reaching $369.67. The stock had a trading volume of 1,184,850 shares, compared to its average volume of 1,354,372. The firm has a 50-day moving average of $367.06 and a 200-day moving average of $373.49. Stryker Co. has a fifty-two week low of $314.93 and a fifty-two week high of $406.19. The company has a market capitalization of $141.10 billion, a price-to-earnings ratio of 47.64, a price-to-earnings-growth ratio of 2.93 and a beta of 0.93. The company has a current ratio of 1.95, a quick ratio of 1.32 and a debt-to-equity ratio of 0.59.

Stryker (NYSE:SYK - Get Free Report) last posted its earnings results on Tuesday, January 28th. The medical technology company reported $4.01 earnings per share for the quarter, topping analysts' consensus estimates of $3.87 by $0.14. Stryker had a net margin of 13.25% and a return on equity of 23.58%. During the same quarter last year, the business posted $3.46 EPS. As a group, sell-side analysts anticipate that Stryker Co. will post 13.47 EPS for the current year.

Stryker Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Wednesday, April 30th. Investors of record on Monday, March 31st will be given a dividend of $0.84 per share. This represents a $3.36 annualized dividend and a yield of 0.91%. The ex-dividend date is Monday, March 31st. Stryker's dividend payout ratio is currently 43.30%.

Insiders Place Their Bets

In related news, Director Allan C. Golston sold 2,458 shares of the company's stock in a transaction that occurred on Tuesday, February 18th. The stock was sold at an average price of $383.07, for a total value of $941,586.06. Following the sale, the director now directly owns 14,895 shares in the company, valued at $5,705,827.65. This represents a 14.16 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, Director Ronda E. Stryker sold 201,392 shares of the firm's stock in a transaction that occurred on Friday, January 31st. The stock was sold at an average price of $392.24, for a total transaction of $78,993,998.08. Following the transaction, the director now owns 3,642,075 shares of the company's stock, valued at approximately $1,428,567,498. The trade was a 5.24 % decrease in their position. The disclosure for this sale can be found here. Company insiders own 5.90% of the company's stock.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.